Rani Therapeutics Holdings, Inc.

NASDAQ•RANI

CEO: Mr. Mir A. Imran

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-07-30

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Contact Information

2051 Ringwood Avenue, San Jose, CA, 95131, United States

408-457-3700

www.ranitherapeutics.com

Market Cap

$94.16M

P/E (TTM)

-1.7

17.5

Dividend Yield

52W High

$3.87

52W Low

$0.39

52W Range

26%

Rank56Top 81.7%

2.5

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.12-50.00%

4-Quarter Trend

FCF

-$5.06M-40.68%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Net loss attributable to RANI narrowed 20.2% to $5.4M for Q3 2025, reflecting improved operational efficiency compared to prior period.

Operating Expenses Under Control R&D expenses dropped 47.8% to $3.2M in Q3 2025 due to cost containment efforts, including temporary pause of certain programs.

Major Financing Closed October Company secured approximately $60.3M gross proceeds in October 2025 Private Placement, alleviating immediate going concern doubts.

Chugai Collaboration Revenue Stream New collaboration provides $10.0M upfront payment expected soon, plus potential milestones up to $180.0M and royalties.

Risk Factors

Need for Future Capital Expect continued operating losses requiring substantial additional capital raises soon to fund platform development and clinical trials.

Collaboration Success Uncertainty Milestone and royalty payments depend on successful development, regulatory approval, and commercialization of the Chugai collaboration Product.

Nasdaq Listing Compliance History Recently regained compliance with Minimum Bid Price and MVLS requirements; future compliance is not guaranteed, risking delisting.

Global Trade Policy Risks International trade policies, tariffs, and geopolitical factors pose risks to supply chain complexity and manufacturing costs.

Outlook

RaniPill HC Clinical Initiation Intends to initiate Phase 1 clinical testing for the high-capacity RaniPill HC device by the end of 2025.

RT-114 Phase 1 Trial Planned Plans to initiate a Phase 1 trial for RT-114, a GLP-1/GLP-2 agonist, by the end of 2025.

Stockholder Approval Sought Agreed to seek stockholder approval within 75 days for shares issuable upon exercise of Common Warrants from Private Placement.

Manufacturing Optimization Continues Will continue to scale and optimize automated manufacturing processes, requiring material future capital outlays and fixed costs.

Peer Comparison

Revenue (TTM)

IPHA

$36.93M

-61.2%

SGMO

$32.88M

-37.1%

TNXP

$10.30M

-8.8%

Gross Margin (Latest Quarter)

SGMO

100.0%

+0.0pp

APLT

100.0%

+0.0pp

CRDF

8.2%

+5842.4pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CYBN	$413.02M	-1.7	-61.5%	15.9%
ELTX	$188.12M	-4.2	-977.7%	19.7%
MOLN	$176.15M	-2.3	-51.0%	1.4%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 25, 2026

EPS:-$0.05

Revenue:$5.00M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data